Loading...

Femasys Inc.

FEMYNASDAQ
Healthcare
Medical - Instruments & Supplies
$0.57
$0.003(0.62%)

Femasys Inc. (FEMY) Financial Performance & Income Statement Overview

Explore the financials of Femasys Inc. (FEMY), including yearly and quarterly data on income, cash flow, and balance sheets.

Revenue Growth
51.97%
51.97%
Operating Income Growth
-22.59%
22.59%
Net Income Growth
-32.07%
32.07%
Operating Cash Flow Growth
-72.37%
72.37%
Operating Margin
-1015.00%
1015.00%
Gross Margin
53.71%
53.71%
Net Profit Margin
-1113.68%
1113.68%
ROE
-713.69%
713.69%
ROIC
224.43%
224.43%

Femasys Inc. (FEMY) Income Statement & Financial Overview

Access detailed annual and quarterly income data for Femasys Inc. FEMY financial performance.

MetricQ1 2025Q4 2024Q3 2024Q2 2024
Revenue$341264.00$581576.00$554908.00$221484.00
Cost of Revenue$117266.00$192407.00$190839.00$73125.00
Gross Profit$223998.00$389169.00$364069.00$148359.00
Gross Profit Ratio$0.66$0.67$0.66$0.67
R&D Expenses$2.97M$2.17M$2.30M$1.98M
SG&A Expenses$2.63M$2.86M$3.10M$2.59M
Operating Expenses$5.68M$5.11M$5.48M$4.63M
Total Costs & Expenses$5.80M$5.30M$5.67M$4.70M
Interest Income$19029.00$49504.00$124028.00$184138.00
Interest Expense$459449.00$440422.00$413290.00$388311.00
Depreciation & Amortization$217060.00$218255.00$215718.00$214135.00
EBITDA-$5.22M-$4.45M-$4.78M-$4.08M
EBITDA Ratio-$15.31-$7.66-$8.61-$18.44
Operating Income-$5.46M-$4.72M-$5.12M-$4.48M
Operating Income Ratio-$16.001-$8.12-$9.22-$20.24
Other Income/Expenses (Net)-$440420.00-$390918.00-$289262.00-$204173.00
Income Before Tax-$5.90M-$5.11M-$5.41M-$4.69M
Income Before Tax Ratio-$17.29-$8.79-$9.75-$21.16
Income Tax Expense-$4188.00$10194.00$1158.00-$1750.00
Net Income-$5.90M-$5.12M-$5.41M-$4.68M
Net Income Ratio-$17.28-$8.81-$9.75-$21.15
EPS-$0.23-$0.23-$0.24-$0.21
Diluted EPS-$0.23-$0.23-$0.24-$0.21
Weighted Avg Shares Outstanding$25.15M$22.80M$22.23M$22.22M
Weighted Avg Shares Outstanding (Diluted)$25.15M$22.80M$22.23M$22.22M

Over the past four quarters, Femasys Inc. demonstrated steady revenue growth, increasing from $221484.00 in Q2 2024 to $341264.00 in Q1 2025. Operating income reached -$5.46M in Q1 2025, maintaining a consistent -1600% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at -$5.22M, reflecting operational efficiency. Net income dropped to -$5.90M, with EPS at -$0.23. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;